Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy

키워드

참고문헌 (145)

1. Coley WB, "Contribution to the knowledge of sarcoma", Ann Surg, 14, pp.199~220 (1891)
2. Kirkwood JM, "Immunotherapy of cancer in 2012", CA Cancer J Clin, 62, pp.309~335 (2012)
3. Small EJ, "Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T(APC8015)in patients with metastatic, asymptomatic hormone refractory prostate cancer", J Clin Oncol, 24, pp.3089~3094 (2006)
4. KantoffPW, "Sipuleucel-T immunotherapy for castration-resistant prostate cancer", N Engl J Med, 363, pp.411~422 (2010)
5. Lee JB, "Clinical insights into novel immune checkpoint inhibitors", Front Pharmacol, 12, pp.681320~ (2021)
6. Sengupta R, "Aacr cancer progress report 2021 : discovery science driving clinical breakthroughs", Clin Cancer Res, 27, pp.5757~5759 (2021)
7. Seongju Jeong, "Co-Stimulatory Receptors in Cancers and Their Implications for Cancer Immunotherapy", Immune Network, 20(1), pp.1~20 (2020), 대한면역학회[DOI]
8. Ha SJ, "Manipulating both the inhibitory and stimulatory immune system towards the success of therapeutic vaccination against chronic viral infections", Immunol Rev, 223, pp.317~333 (2008)
9. Brunet JF, "A new member of the immunoglobulin superfamily--CTLA-4", Nature, 328, pp.267~270 (1987)
10. Linsley PS, "CTLA-4 is a second receptor for the B cell activation antigen B7", J Exp Med, 174, pp.561~569 (1991)
11. Lenschow DJ, "Longterm survival of xenogeneic pancreatic islet grafts induced by CTLA4lg", Science, 257, pp.789~792 (1992)
12. Linsley PS, "Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule", Science, 257, pp.792~795 (1992)
13. Walunas TL, "CTLA-4 can function as a negative regulator of T cell activation", Immunity, 1, pp.405~413 (1994)
14. Krummel MF, "CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation", J Exp Med, 182, pp.459~465 (1995)
15. Waterhouse P, "Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4", Science, 270, pp.985~988 (1995)
16. Tivol EA, "Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4", Immunity, 3, pp.541~547 (1995)
17. Ishida Y, "Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death", EMBO J, 11, pp.3887~3895 (1992)
18. Nishimura H, "Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor", Immunity, 11, pp.141~151 (1999)
19. Nishimura H, "Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice", Science, 291, pp.319~322 (2001)
20. Dong H, "B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion", Nat Med, 5, pp.1365~1369 (1999)
21. Tseng SY, "B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells", J Exp Med, 193, pp.839~846 (2001)
22. Freeman GJ, "Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation", J Exp Med, 192, pp.1027~1034 (2000)
23. Latchman Y, "PD-L2 is a second ligand for PD-1 and inhibits T cell activation", Nat Immunol, 2, pp.261~268 (2001)
24. Dong H, "B7-H1 determines accumulation and deletion of intrahepatic CD8(+)T lymphocytes", Immunity, 20, pp.327~336 (2004)
25. Latchman YE, "PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells", Proc Natl Acad Sci U S A, 101, pp.10691~10696 (2004)
26. Zhang Y, "Regulation of T cell activation and tolerance by PDL2", Proc Natl Acad Sci U S A, 103, pp.11695~11700 (2006)
27. Liang SC, "PD-L1 and PD-L2have distinct roles in regulating host immunity to cutaneous leishmaniasis", Eur J Immunol, 36, pp.58~64 (2006)
28. Leach DR, "Enhancement of antitumor immunity by CTLA-4 blockade", Science, 271, pp.1734~1736 (1996)
29. Hodi FS, "Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients", Proc Natl Acad Sci U S A, 100, pp.4712~4717 (2003)
30. Phan GQ, "Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma", Proc Natl Acad Sci U S A, 100, pp.8372~8377 (2003)
31. Hodi FS, "Improved survival with ipilimumab in patients with metastatic melanoma", N Engl J Med, 363, pp.711~723 (2010)
32. Robert C, "Ipilimumab plus dacarbazine for previously untreated metastatic melanoma", N Engl J Med, 364, pp.2517~2526 (2011)
33. Iwai Y, "Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade", Proc Natl Acad Sci U S A, 99, pp.12293~12297 (2002)
34. Dong H, "Tumor-associated B7-H1 promotes T-cell apoptosis : a potential mechanism of immune evasion", Nat Med, 8, pp.793~800 (2002)
35. Hirano F, "Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity", Cancer Res, 65, pp.1089~1096 (2005)
36. Barber DL, "Restoring function in exhausted CD8 T cells during chronic viral infection", Nature, 439, pp.682~687 (2006)
37. Brahmer JR, "Phase I study of single-agent anti-programmed death-1(MDX-1106)in refractory solid tumors : safety, clinical activity, pharmacodynamics, and immunologic correlates", J Clin Oncol, 28, pp.3167~3175 (2010)
38. Topalian SL, "Safety, activity, and immune correlates of anti-PD-1 antibody in cancer", N Engl J Med, 366, pp.2443~2454 (2012)
39. Brahmer JR, "Safety and activity of anti-PD-L1 antibody in patients with advanced cancer", N Engl J Med, 366, pp.2455~2465 (2012)
40. Hamid O, "Safety and tumor responses with lambrolizumab(anti-PD-1)in melanoma", N Engl J Med, 369, pp.134~144 (2013)
41. Larkin J, "Combined nivolumab and ipilimumab or monotherapy in untreated melanoma", N Engl J Med, 373, pp.23~34 (2015)
42. Balar AV, "Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma : a single-arm, multicentre, phase 2 trial", Lancet, 389, pp.67~76 (2017)
43. Burtness B, "Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck(KEYNOTE-048) : a randomised, open-label, phase 3 study", Lancet, 394, pp.1915~1928 (2019)
44. Gandhi L, "Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer", N Engl J Med, 378, pp.2078~2092 (2018)
45. Hellmann MD, "Nivolumab plus ipilimumab in advanced non-small-cell lung cancer", N Engl J Med, 381, pp.2020~2031 (2019)
46. Hodi FS, "Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma : 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2trial", Lancet Oncol, 17, pp.1558~1568 (2016)
47. Horn L, "First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer", N Engl J Med, 379, pp.2220~2229 (2018)
48. Langer CJ, "Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer : a randomised, phase 2 cohort of the open-label KEYNOTE-021 study", Lancet Oncol, 17, pp.1497~1508 (2016)
49. Mok TS, "Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer(KEYNOTE-042) : a randomised, open-label, controlled, phase 3 trial", Lancet, 393, pp.1819~1830 (2019)
50. Motzer RJ, "Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma", N Engl J Med, 380, pp.1103~1115 (2019)
51. Paz-Ares L, "Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer", N Engl J Med, 379, pp.2040~2051 (2018)
52. Reck M, "Pembrolizumab versus chemotherapy for PD-l1-positive non-small-cell lung cancer", N Engl J Med, 375, pp.1823~1833 (2016)
53. Reck M, "Updated analysis of keynote-024 : pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-l1 tumor proportion score of 50% or greater", J Clin Oncol, 37, pp.537~546 (2019)
54. Rini BI, "Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma", N Engl J Med, 380, pp.1116~1127 (2019)
55. Schmid P, "Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer", N Engl J Med, 379, pp.2108~2121 (2018)
56. Bajorin DF, "Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma", N Engl J Med, 384, pp.2102~2114 (2021)
57. Eggermont AM, "Adjuvant pembrolizumab versus placebo in resected stage iii melanoma", N Engl J Med, 378, pp.1789~1801 (2018)
58. Kelly RJ, "Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer", N Engl J Med, 384, pp.1191~1203 (2021)
59. Schmid P, "Pembrolizumab for early triple-negative breast cancer", N Engl J Med, 382, pp.810~821 (2020)
60. Wakelee HA, "Impower010 : Primary results of a phase iii global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage ib-iiia non-small cell lung cancer(nsclc)", J Clin Oncol, 39(15_suppl), pp.8500~8500 (2021)
61. Cetin K, "Survival by histologic subtype in stage IV nonsmall cell lung cancer based on data from the Surveillance, Epidemiology and End Results Program", Clin Epidemiol, 3, pp.139~148 (2011)
62. Paz-Ares LG, "PARAMOUNT : Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer", J Clin Oncol, 31, pp.2895~2902 (2013)
63. Schiller JH, "Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer", N Engl J Med, 346, pp.92~98 (2002)
64. Ettinger DS, "NCCN guidelines insights : non-small cell lung cancer, version 2. 2021", J Natl Compr Canc Netw, 19, pp.254~266 (2021)
65. Vaddepally RK, "Review of indications of fda-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence", Cancers(Basel), 12, pp.738~ (2020)
66. Steuer CE, "Advances in immunotherapy and implications for current practice in nonsmall-cell lung cancer", JCO Oncol Pract, 17, pp.662~668 (2021)
67. Garon EB, "Pembrolizumab for the treatment of non-small-cell lung cancer", N Engl J Med, 372, pp.2018~2028 (2015)
68. Brahmer J, "Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer", N Engl J Med, 373, pp.123~135 (2015)
69. Herbst RS, "Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer(KEYNOTE-010) : a randomised controlled trial", Lancet, 387, pp.1540~1550 (2016)
70. Borghaei H, "Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer", N Engl J Med, 373, pp.1627~1639 (2015)
71. Rittmeyer A, "Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer(OAK) : a phase 3, open-label, multicentre randomised controlled trial", Lancet, 389, pp.255~265 (2017)
72. Herbst RS, "Atezolizumab for first-line treatment of pd-l1-selected patients with NSCLC", N Engl J Med, 383, pp.1328~1339 (2020)
73. Sezer A, "Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50% : a multicentre, open-label, global, phase 3, randomised, controlled trial", Lancet, 397, pp.592~604 (2021)
74. Zhang P, "Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy", Cancer Sci, 107, pp.1563~1571 (2016)
75. Apetoh L, "Combining immunotherapy and anticancer agents : the right path to achieve cancer cure?", Ann Oncol, 26, pp.1813~1823 (2015)
76. Galluzzi L, "Immunological effects of conventional chemotherapy and targeted anticancer agents", Cancer Cell, 28, pp.690~714 (2015)
77. Socinski MA, "IMpower150 Study Group. Atezolizumab for first-line treatment of metastatic nonsquamous nsclc", N Engl J Med, 378, pp.2288~2301 (2018)
78. Rodríguez-Abreu D, "Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC : protocol-specified final analysis from KEYNOTE-189", Ann Oncol, 32, pp.881~895 (2021)
79. Paz-Ares L, "A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC : Protocol-specified final analysis of keynote-407", J Thorac Oncol, 15, pp.1657~1669 (2020)
80. Sheth S, "Current and emerging therapies for patients with advanced non-small-cell lung cancer", Am J Health Syst Pharm, 67(Suppl 1), pp.S9~S14 (2010)
81. Soldera SV, "Update on the treatment of metastatic squamous non-small cell lung cancer in new era of personalized medicine", Front Oncol, 7, pp.50~ (2017)
82. Paz-Ares L, "First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer(CheckMate 9LA) : an international, randomised, open-label, phase 3 trial", Lancet Oncol, 22, pp.198~211 (2021)
83. Reck M, "First-line nivolumab(NIVO)plus ipilimumab(IPI)plus two cycles of chemotherapy(chemo)versus chemo alone(4 cycles)in patients with advanced non-small cell lung cancer(NSCLC) : Two-year update from checkmate 9la", J Clin Oncol, 39(15 Suppl), pp.9000~ (2021)
84. Antonia SJ, "Durvalumab after chemoradiotherapy in stage iii non–small-cell lung cancer", N Engl J Med, 377, pp.1919~1929 (2017)
85. Spigel DR, "Five-year survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC : an update from the pacific trial", J Clin Oncol, 15(Suppl), pp.8511~ (2021)
86. Jabbour SK, "Keynote-799: Phase 2 trial of pembrolizumab plus platinum chemotherapy and radiotherapy for unresectable, locally advanced, stage 3 nsclc", J Clin Oncol, 39(15 Suppl), pp.8512~ (2021)
87. Peters S, "Progression-free and overall survival for concurrent nivolumab with standard concurrent chemoradiotherapy in locally advanced stage IIIa-b NSCLC : Results from the European thoracic oncology platform NICOLAS phase ii trial(European thoracic oncology platform 6–14)", J Thorac Oncol, 16, pp.278~288 (2021)
88. Lin SH, "Phase ii trial of concurrent atezolizumab with chemoradiation for unresectable NSCLC", J Thorac Oncol, 15, pp.248~257 (2020)
89. Bai R, "Neoadjuvant and adjuvant immunotherapy : opening new horizons for patients with early-stage non-small cell lung cancer", Front Oncol, 10, pp.575472~ (2020)
90. 이용준, "Clinical Perspectives to Overcome Acquired Resistance to Anti–Programmed Death-1 and Anti–Programmed Death Ligand-1 Therapy in Non-Small Cell Lung Cancer", Molecules and Cells, 44(5), pp.363~373 (2021), 한국분자세포생물학회[DOI]
91. Rodriguez-Abreu D, "Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE)", J Clin Oncol, 38(15 Suppl), pp.9503~ (2020)
92. Pauken KE, "Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade", Science, 354, pp.1160~1165 (2016)
93. Sen DR, "The epigenetic landscape of T cell exhaustion", Science, 354, pp.1165~1169 (2016)
94. Turner SJ, "Can T cells be too exhausted to fight back", Science, 354, pp.1104~1105 (2016)
95. Ghoneim HE, "De novo epigenetic programs inhibit PD-1 blockade-mediated T cell rejuvenation", Cell, 170, pp.142~157 (2017)
96. Im SJ, "Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy", Nature, 537, pp.417~421 (2016)
97. He R, "Follicular CXCR5-expressing CD8(+)T cells curtail chronic viral infection", Nature, 537, pp.412~428 (2016)
98. Utzschneider DT, "T cell factor 1-expressing memory-like cd8(+)T cells sustain the immune response to chronic viral infections", Immunity, 45, pp.415~427 (2016)
99. Wu T, "The TCF1-Bcl6 axis counteracts type I interferon to repress exhaustion and maintain T cell stemness", Sci Immunol, 1, pp.1~ (2016)
100. Leong YA, "CXCR5(+)follicular cytotoxic T cells control viral infection in B cell follicles", Nat Immunol, 17, pp.1187~1196 (2016)
101. Miller BC, "Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade", Nat Immunol, 20, pp.326~336 (2019)
102. Kurtulus S, "Checkpoint blockade immunotherapy induces dynamic changes in PD-1(-)CD8(+)tumorinfiltrating T cells", Immunity, 50, pp.181~194 (2019)
103. Chu F, "CXCR5+CD8+ T cells are a distinct functional subset with an antitumor activity", Leukemia, 33, pp.2640~2653 (2019)
104. Jansen CS, "An intra-tumoral niche maintains and differentiates stem-like CD8 T cells", Nature, 576, pp.465~470 (2019)
105. Eberhardt CS, "Functional HPV-specific PD-1+ stem-like CD8 T cells in head and neck cancer", Nature, 597, pp.279~284 (2021)
106. Hudson WH, "Proliferating transitory T cells with an effector-like transcriptional signature emerge from PD-1(+)stem-like CD8(+)T cells during chronic infection", Immunity, 51, pp.1043~1058 (2019)
107. Beltra JC, "Developmental relationships of four exhausted CD8(+)T cell subsets reveals underlying transcriptional and epigenetic landscape control mechanisms", Immunity, 52, pp.825~841 (2020)
108. Se Jin Im, "Re-defining T-Cell Exhaustion: Subset, Function, and Regulation", Immune Network, 20(1), pp.1~19 (2020), 대한면역학회[DOI]
109. Kamphorst AO, "Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent", Science, 355, pp.1423~1427 (2017)
110. Hui E, "T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition", Science, 355, pp.1428~1433 (2017)
111. Clouthier DL, "Costimulation, a surprising connection for immunotherapy", Science, 355, pp.1373~1374 (2017)
112. Khan O, "TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion", Nature, 571, pp.211~218 (2019)
113. Alfei F, "TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection", Nature, 571, pp.265~269 (2019)
114. Scott AC, "TOX is a critical regulator of tumour-specific T cell differentiation", Nature, 571, pp.270~274 (2019)
115. Yao C, "Single-cell RNA-seq reveals TOX as a key regulator of CD8+ T cell persistence in chronic infection", Nat Immunol, 20, pp.890~901 (2019)
116. Seo H, "TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8+ T cell exhaustion", Proc Natl Acad Sci U S A, 116, pp.12410~12415 (2019)
117. Kim CG, "VEGF-A drives TOX-dependent T cell exhaustion in anti-PD-1-resistant microsatellite stable colorectal cancers", Sci Immunol, 4, pp.4~ (2019)
118. Kim K, "Single-cell transcriptome analysis reveals TOX as a promoting factor for T cell exhaustion and a predictor for anti-PD-1 responses in human cancer", Genome Med, 12, pp.22~ (2020)
119. Wang X, "TOX promotes the exhaustion of antitumor CD8+ T cells by preventing PD1 degradation in hepatocellular carcinoma", J Hepatol, 71, pp.731~741 (2019)
120. Blank CU, "Defining ‘T cell exhaustion’", Nat Rev Immunol, 19, pp.665~674 (2019)
121. van der Leun AM, "CD8+ T cell states in human cancer : insights from single-cell analysis", Nat Rev Cancer, 20, pp.218~232 (2020)
122. Kim MJ, "Differential role of PD-1 expressed by various immune and tumor cells in the tumor immune microenvironment : expression, function, therapeutic efficacy, and resistance to cancer immunotherapy", Front Cell Dev Biol, 9, pp.767466~ (2021)
123. Zha H, "Non-canonical PD-1signaling in cancer and its potential implications in clinic", J Immunother Cancer, 9, pp.9~ (2021)
124. Gordon SR, "PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity", Nature, 545, pp.495~499 (2017)
125. Park HJ, "Tumor-infiltrating regulatory T cells delineated by upregulation of PD-1 and inhibitory receptors", Cell Immunol, 278, pp.76~83 (2012)
126. Kim HR, "Tumor microenvironment dictates regulatory T cell phenotype : upregulated immune checkpoints reinforce suppressive function", J Immunother Cancer, 7, pp.339~ (2019)
127. Son J, "Tumor-infiltrating regulatory T-cell accumulation in the tumor microenvironment is mediated by IL33", ST2 signaling, 2020, pp.8, 1393~1406
128. Park HJ, "PD-1upregulated on regulatory T cells during chronic virus infection enhances the suppression of CD8+ T cell immune response via the interaction with PD-L1 expressed on CD8+ T cells", J Immunol, 194, pp.5801~5811 (2015)
129. Yoshida K, "Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells", BMC Cancer, 20, pp.25~ (2020)
130. Stathopoulou C, "PD-1 inhibitory receptor downregulates asparaginyl endopeptidase and maintains foxp3 transcription factor stability in induced regulatory T cells", Immunity, 49, pp.247~263 (2018)
131. Leung CS, "Single-cell transcriptomics reveal that PD-1 mediates immune tolerance by regulating proliferation of regulatory T cells", Genome Med, 10, pp.71~ (2018)
132. Asano T, "PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy", Blood, 129, pp.2186~2197 (2017)
133. Kamada T, "PD-1+regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer", Proc Natl Acad Sci U S A, 116, pp.9999~10008 (2019)
134. Kumagai S, "The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies", Nat Immunol, 21, pp.1346~1358 (2020)
135. Topalian SL, "Neoadjuvant checkpoint blockade for cancer immunotherapy", Science, 367, pp.367~ (2020)
136. Philip M, "CD8+ T cell differentiation and dysfunction in cancer", Nat Rev Immunol (2021)[DOI]
137. Sautès-Fridman C, "Tertiary lymphoid structures in the era of cancer immunotherapy", Nat Rev Cancer, 19, pp.307~325 (2019)
138. Schumacher TN, "Tertiary lymphoid structures in cancer", Science, 375, pp.eabf9419~ (2022)
139. Fairfax BP, "Peripheral CD8+ T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanoma", Nat Med, 26, pp.193~199 (2020)
140. Valpione S, "Immune-awakening revealed by peripheral T cell dynamics after one cycle of immunotherapy", Nat Can, 1, pp.210~221 (2020)
141. Wu TD, "Peripheral T cell expansion predicts tumour infiltration and clinical response", Nature, 579, pp.274~278 (2020)
142. Burger ML, "Antigen dominance hierarchies shape TCF1(+)progenitor CD8 T cell phenotypes in tumors", Cell, 184, pp.4996~5014 (2021)
143. Connolly KA, "A reservoir of stem-like CD8+ T cells in the tumor-draining lymph node preserves the ongoing antitumor immune response", Sci Immunol, 6, pp.eabg7836~ (2021)
144. Lucca LE, "Circulating clonally expanded T cells reflect functions of tumor-infiltrating T cells", J Exp Med, 218, pp.218~ (2021)
145. Schenkel JM, "Conventional type I dendritic cells maintain a reservoir of proliferative tumor-antigen specific TCF-1(+)CD8(+)T cells in tumor-draining lymph nodes", Immunity, 54, pp.2338~2353 (2021)

관련 논문AI추천